Day 5 multiomics signatures in never responders highlight key altered pathways in the VTE cohort. (A) Significant differences in protein and metabolite levels between VTE development status groups were assessed specifically for patients who responded poorly to enoxaparin, at each monitored time point. The day 5 time point exhibited the highest number of significantly different features. (B) Pairwise comparison of features detected in both VTE status groups, specifically for day 5 plasma samples. (C) PLS-DA of day 5 multiomic signatures, categorized by VTE status. (D) The top 25 molecular features identified by the PLS-DA model that contributed to the differentiation between VTE status. (E) Heat map presentation of the top 50 molecular features that showed significant differences between the VTE status groups at day 5, as determined by the t test. Feature names were colored according to key thromboinflammatory pathways of interest to this analysis. Orange, complement activation; red: blood coagulation; dark blue, immune response; light blue, acute phase response.